| 000 | 01449 a2200397 4500 | ||
|---|---|---|---|
| 005 | 20250515154103.0 | ||
| 264 | 0 | _c20090427 | |
| 008 | 200904s 0 0 eng d | ||
| 022 | _a1365-2796 | ||
| 024 | 7 |
_a10.1111/j.1365-2796.2008.02052.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aJädersten, M | |
| 245 | 0 | 0 |
_aMyelodysplastic syndromes: biology and treatment. _h[electronic resource] |
| 260 |
_bJournal of internal medicine _cMar 2009 |
||
| 300 |
_a307-28 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Review | ||
| 650 | 0 | 4 |
_aAntineoplastic Agents _xtherapeutic use |
| 650 | 0 | 4 | _aBlood Transfusion |
| 650 | 0 | 4 |
_aChromosomes, Human, Pair 5 _xgenetics |
| 650 | 0 | 4 | _aDisease Progression |
| 650 | 0 | 4 |
_aErythropoietin _xtherapeutic use |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunosuppressive Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aIron Chelating Agents _xtherapeutic use |
| 650 | 0 | 4 | _aLenalidomide |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMyelodysplastic Syndromes _xclassification |
| 650 | 0 | 4 | _aRecombinant Proteins |
| 650 | 0 | 4 | _aSequence Deletion |
| 650 | 0 | 4 |
_aThalidomide _xanalogs & derivatives |
| 650 | 0 | 4 | _aWorld Health Organization |
| 700 | 1 | _aHellström-Lindberg, E | |
| 773 | 0 |
_tJournal of internal medicine _gvol. 265 _gno. 3 _gp. 307-28 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/j.1365-2796.2008.02052.x _zAvailable from publisher's website |
| 999 |
_c18589111 _d18589111 |
||